Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

Plain-language summary

This study evaluated the medicine Axitinib in combination with Cisplatin and Capecitabine in patients with advanced gastric (stomach) cancer. It was open to patients with confirmed Stage IV advanced stomach cancer and adequate blood and kidney values. Sponsored by Pfizer, the study was conducted in Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

Pfizer

Intervention

axitinib, capecitabine, cisplatin

Start date

4/1/2009

Estimated completion

10/1/2012

Countries

Japan, South Korea

Related genes

Locations

• Kashiwa, Japan
• Yufu, Japan
• Goyang-si, South Korea
• Seongnam-si, South Korea
• Seoul, South Korea

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* confirmed diagnosis of stomach cancer
* advanced stomach cancer of stage IV
* adequate blood chemistry, blood counts and kidney function
* willing to participate to study requirements and sign an informed consent document

Exclusion Criteria:

* prior chemotherapy for stomach cancer in its advanced stage
* excessive toxicities related to prior therapies
* pregnant or breastfeeding patients